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determine the treatment outcome. In this context, central 
questions in clinical particle radiobiology focus on the 
validation of RBE models, on the decipherment of underlying 
mechanisms, and on the question if a differential RBE 
between tumor and normal tissues exist. 
The presentation will summarize the present knowledge of 
normal tissue effects after particle therapy with special 
emphasis on the RBE and its dependencies on physical and 
biological factors, on examples how RBEs for normal tissues 
are determined in preclinical models and from patient data 
as well as on needs of future investigations. 
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There is growing evidence that the presence of stem cells is 
an important determinant for treatment outcome, not only 
for normal tissues but also tumours. Tissue/cancer stem cells 
are considered to be a main driver for tissue tolerance and 
regeneration and tumour growth, therapy resistance and 
relapse of disease. Recent developments in the field of adult 
stem cell technology have provided the possibilities of the 3D 
culture of multiple tissues and tumours as stem cell 
derived/containing spheres and organoids. These organoids 
closely resemble the composition of an organ or tumour and 
upon transplantation regrow the tissue and tumour closely 
resembling the original. Moreover, it has been suggested that 
adult stem are a critical target for radiation carcinogenesis. 
Stem cells are able to self-renew in tissues for a long period 
of time, which increases their lifetime risk of accumulating 
mutations required for cancer formation. Now using organoid 
cultures of salivary gland and thyroid gland we are able to 
study the radiation response of tissue and cancer stem cells 
in vitro. Examples of the response of spheres and organoids 
to X-rays, Carbon ions and Neutrons will be shown. Remaining 
organoid formation potential, self-renewal potential, stem 
cell marker expression, and differentiation potential, DNA 
repair and gene expression upon irradiation will be shown. 
Moreover, (xeno-)transplantation experiments allow 
assessment of actual regeneration potential of (cancer)stem 
cells. As such we now are potentially able to monitor and 
modulate the in vitro the response of tissues and tumours 
upon (chemo-) radiation and relate these to patient response 
and radiation-induced carcinogenesis. 
This project was financed by the EU, as part of the FP7 
project ANDANTE. 
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EGFR-inhibitors have been used in several clinical settings 
during the last decade and side-effects related to normal 
tissues like the skin, mucosa and kidney has been well 
described. However, when EGFR-inhibitors are combined with 
radiotherapy, then different skin and mucosa toxicity profiles 
can be seen. The presentation will focus on typical as well as 
atypical clinical presentations of the combined treatment 
modalities in skin and mucosa. This will be with an emphasis 
on recent data from a randomized phase III trial on 
chemoradiation plus/minus EGFR-inhibition. The clinical 
presentations will be explained with references to the 
current knowledge of the biology of skin toxicity. 
Treatment options for acute side-effects in skin and mucosa 
after bio-radiotherapy is rarely causal. A few attempts have 
been done; some of them aiming to rephosphorylate the EGF-
receptor in the skin with vitamin K3. The talk will discuss the 
available data from these studies.  
Across several tumour sites and for different EGFR-inhibitors, 
a correlation between skin toxicity and tumour response has 
also been documented. The reason for this correlation is not 
obvious but probably related to genetic alterations or certain 
genetic variations that are shared between tumour and 
normal tissue like skin and mucosa. At present, it is not 
possible to predict which patients that will develop severe 
skin toxicity and thereby potentially benefit from EGFR-
inhibition in terms of tumour response. However, emerging 
data suggests that certain single nucleotide polymorphisms in 
the EGF-gene that alter the ligand-receptor binding might be 
responsible for the observed clinical correlation. These data 
will be discussed in the light of EGFR-inhibition in 
combination with chemotherapy and/or radiotherapy. 
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Clinical applications: High dose rate endorectal 
brachytherapy (HDREBT) is a highly targeted radiation 
modality that uses Magnetic Resonance Imaging (MRI) for 
target definition and computed tomography (CT) based 
treatment planning. The treatment is given on an outpatient 
basis and does not require anesthesia but conscious sedation 
as needed. In the era of Total Mesorectal Excision (TME) 
surgery, pre-operative external beam radiation therapy 
(EBRT) contributes by reducing the local recurrence from 11 
to 5%. HDREBT was tested and validated clinically as an 
effective neoadjuvant modality for tumor down-staging in 
patients with operable rectal cancer having an advantage 
over the EBRT in providing limited normal tissues exposure to 
radiation. In patients unfitted for surgery, HDREBT was used 
as a boost after an initial course of external beam therapy to 
improve local control. 
Technical applications: Pre-treatment includes imaging with 
pelvic MRI and tumor mapping with radio-opaque clips to 
improve the accuracy of treatment delivery. The patient is 
planned at the CT-simulator in supine position after bowel 
preparation with the Oncosmart intracavitary mold applicator 
(Elekta). Position of the applicator is adjusted to the level of 
the radio-opaque clips, as seen on the pilot, prior to CT 
scanning. Subsequently, the CTV contouring is performed 
based on MRI images. In the pre-operative setting, dose 
distribution is optimized in order for the target to receive 26 
Gy in 4 fractions. In the boost setting, a repeated pelvic MRI 
is obtained 2-3 weeks after the external beam radiation 
treatment, period that allows tumor down-sizing, and the 
total dose 30 Gy is given weekly in 3 fractions. For this 
treatment the same applicator is used with tungsten shielding 
rod placed in the central applicator hole to protect the 
contralateral healthy tissue. Dose is optimized on the 
residual tumor gross tumor volume (GTV) with the addition of 
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a double balloon system introduced to optimize dose 
distribution. 
Toxicity and long-term oncological results: In the neo-
adjuvant setting, grade 3 radiation proctitis is observed in 
less than 0.5% of treated cases 7-10 days after treatment 
completion. In the boost setting, proctitis is observed 3-4 
weeks after the HDREBT treatment and included rectal 
bleeding in 25% of the patients, out of which 10% with 
anticoagulation required transfusion and plasma-argon 
therapy. In 3 patients with circumferential tumors, rectal 
stenosis was documented. Rectal ulcerations can be observed 
5-9 months after treatment but do improve over time. 
Overall for low T2 and T3 tumors, HDREBT resulted with a 
pCR rate of 27%, with the local recurrence of 4.8 % at 5 years 
with a median follow up time of 62 months. For the medically 
unfitted patients, with HDREBT used as a boost, the local 
control is 65% at a median 28 months follow up time. 
Conclusion: In the present era of rectal preservation, the 
HDEBT represents a highly targeted radiation modality that is 
effective as neo-adjuvant and boost treatment modalities for 
patients with rectal cancer. 
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Surgery main Treatment of rectal cancer often combined 
with neoadjuvant (chemo) radiotherapy (CRT).  
Despite improvement in local control for T2-3(4) tumors, CRT 
failed to improve conservative treatment in rectal cancer. 
Anterior resection is often associated with suboptimal bowel 
function. Organ preservation (whole rectum + anus) is gaining 
interest mainly for early (T1) T2 T3 tumors. 
CXB: a unique technique of trans-rectal endoscopic 
Brachytherapy Evidence Based.  
Mainly pioneered by Papillon in the 1970s the technique is 
presenting a renaissance since 2009 (1) with the manufacture 
of a new machine delivering high dose rate of 50 Kvp X-rays( 
Papillon 50TM). Under direct endoscopic vision control it is 
possible to deliver 30 Gy in 2 minutes in a well-targeted small 
volume (5 cm3). It is a fully ambulatory treatment feasible at 
any age with very low toxicity. The dose distribution is better 
than with Iridium endoluminal HDR brachytherapy and 
radioprotection is easier. The Lyon R 96-02 randomized trial 
(2-3) has demonstrated with a 10 year follow-up that CXB 
boost combined with External beam RT in T2 -3 low rectum 
was able to increase by 30% the rate of clinical complete 
response, of sphincter saving surgery and of organ 
preservation in case of cCR. The rate of perirectal nodal 
relapse is below 5%. 
Present results in France and UK show good results for 
organ preservation in selected T1 T2 and early T3  
In T1 N0 (or malignant polyps) treated with local Excision 
first (63 pts between 1986-2012 in Lyon and Nice), adjuvant 
CXB (50 Gy/ 3 fr/ 3w) achieved local control in 95% of cases 
with good bowel function. In T2 T3 less than ½ circumference 
and < 5cm diameter a combination of CXB and EBRT (or CRT), 
mainly in elderly frail patients, achieved cCR in close to 90% 
of cases (Lyon-Nice: 120 pts) with less than 20% local relapse 
very exceptional in perirectal lymph nodes (4-5). In 
Clatterbridge-Liverppool same results were achieved in the 
recent past years in more than 150 pts. Such combined CXB+ 
CRT appears as a very good option for frail patients or for 
younger patients adamantly refusing an invasive surgery.  
Many challenges remain open 
In operable patients the upcoming OPERA randomized trial 
will like the Lyon R96-02 try to show that CXB in addition to 
CRT (CAP 45) may achieve in T2 T3a-b at least 40% of organ 
preservation with good bowel function. The new machine 
Papillon+TM will bring some technical improvements. But the 
most important issue is that radiation oncologists willing to 
use CXB must get a good clinical practice of rigid rectoscopy 
on an ambulatory basis. 
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In the treatment of rectal cancer, total mesorectal excision 
surgery is now the standard of care. In most patients, surgery 
will be preceded by external beam radiotherapy (EBRT), 
either in a short course (25 Gy/5 fractions) or in a 
conventional schedule (45-50 Gy/25 fractions) with 
chemotherapy. Brachytherapy (BT) is an appealing 
alternative to EBRT.  In comparison to the EBRT, it offers the 
advantage of delivering a high dose of radiation with a rapid 
dose fall-off around the site of interest (tumor target). This 
results in the sparing of normal tissues such as small bowel 
but also the bladder, the prostate, anal sphincter and skin.  
In order to understand why brachytherapy may work as 
replacement for external beam radiotherapy, an exact target 
volume definition for rectal cancer is required, based on 
precise data on the local recurrence patterns. The decision 
which nodal regions should be included in the clinical target 
volume is often topic of discussion. In general, it can be 
stated that the highest risk of lymph node involvement is in 
the mesorectal fat. In addition, the presacral space and the 
internal iliac region are at risk. Depending on the exact 
localization and tumor stage, the obturator nodes, the 
external iliac nodes and the inguinal nodes may sometimes be 
affected. For years, this has lead to a more or less standard 
clinical target volume, including the primary tumor, the 
mesorectal fat and the presacral and internal iliac lymph 
node regions. However, given the limited number of 
recurrences after TME surgery, the standard clinical target 
volume can be seriously questioned. 
Another interesting application of endoluminal brachytherapy 
is the ability to increase the dose on the primary tumour. In 
elderly patients, standard surgery may be hampered by the 
